Feb 02, 2023 8:30am EST Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
Jan 23, 2023 7:00am EST Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
Jan 05, 2023 7:00am EST Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
Dec 29, 2022 11:31am EST Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
Dec 28, 2022 8:30am EST Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
Dec 22, 2022 7:00am EST Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
Nov 21, 2022 7:00am EST Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
Nov 14, 2022 7:00am EST Unicycive Announces Third Quarter Financial Results and Provides Business Update
Nov 10, 2022 7:00am EST Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
